Design Therapeutics, INC 8-K filings

Design Therapeutics announced its second quarter 2026 financial results, highlighting progress in its RESTORE-FA trial for Friedreich's ataxia and initiation of a Phase 1 trial for DT-818 in myotonic dystrophy type 1, while also noting a delay in its FECD program.

Design Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of a director and the ratification of its independent auditor.

Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial for DT-216P2 in Friedreich's Ataxia patients.

Design Therapeutics, Inc. announced the appointment of Dr. David Shapiro to its Board of Directors and Nominating and Corporate Governance Committee, effective March 31, 2026.

Deepa Prasad has resigned from Design Therapeutics' Board of Directors, effective February 1, 2026, due to conflict-avoidance policies related to a new role at a major bank.

Design Therapeutics announced the nomination of DT-818 for Myotonic Dystrophy Type-1, obtained ex-US regulatory clearance, and reported its third quarter 2025 financial results.

Design Therapeutics, Inc. announced the appointment of Justin Gover to its Board of Directors and as Chair of the Compensation Committee, following the resignation of Arsani William, M.D.

Design Therapeutics announced progress across its GeneTAC programs, including early human PK data for DT-216P2 and initiation of a Phase 2 biomarker study for DT-168, alongside its second quarter 2025 financial results.

Design Therapeutics, Inc. announced the successful election of three Class I Directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Design Therapeutics announces favorable Phase 1 data for DT-168 in FECD and provides an update on its Friedreich Ataxia program, along with its first quarter 2025 financial results.

Design Therapeutics reports progress in its GeneTAC programs, including the initiation of a Phase 1 trial for DT-216P2 in Friedreich Ataxia and the completion of dosing in a Phase 1 trial for DT-168 in Fuchs Endothelial Corneal Dystrophy, along with full year 2024 financial results.

Design Therapeutics has updated its corporate presentation for use in meetings with investors and analysts.

Design Therapeutics reported its third quarter 2024 financial results, highlighted progress in its clinical programs, and anticipates key milestones in 2025.

Design Therapeutics announced its second quarter 2024 financial results, highlighting progress in its GeneTAC portfolio and upcoming clinical trial milestones.

Design Therapeutics held its 2024 Annual Meeting of Stockholders, electing a Class III Director and ratifying its independent auditor.

Design Therapeutics announced its first quarter 2024 financial results, highlighting progress in its Friedreich Ataxia, Fuchs Endothelial Corneal Dystrophy, Huntington's Disease, and Myotonic Dystrophy Type-1 programs.

Design Therapeutics reports progress across its GeneTAC platform, including a new drug product for Friedreich Ataxia and IND clearance for Fuchs Endothelial Corneal Dystrophy, alongside its 2023 financial results.